In a patient with asthma, can the dose of Breo (fluticasone furoate/vilanterol) 100 µg/25 µg be increased from one puff daily to two puffs daily when entering the yellow zone of the asthma action plan?

Breo Cannot Be Increased to 2 Puffs Daily for Yellow Zone Management

No, Breo 100/25 mcg should not be increased from 1 puff to 2 puffs daily when entering the yellow zone of an asthma action plan. The FDA-approved labeling explicitly states that "more frequent administration or a greater number of inhalations (more than 1 inhalation daily) of the prescribed strength of BREO ELLIPTA is not recommended as some patients are more likely to experience adverse effects with higher doses," and the maximum recommended dosage is 1 inhalation once daily 1.

FDA-Approved Dosing Constraints

• Breo must be used exactly once every 24 hours – the label explicitly prohibits using it more than 1 time every 24 hours 1.
• Doubling the number of inhalations is contraindicated – increasing from 1 to 2 puffs daily exceeds the approved dosing regimen and increases the risk of adverse effects, particularly from the long-acting beta-agonist vilanterol 1.
• The vilanterol component (25 mcg) is fixed – taking 2 puffs would deliver 50 mcg of vilanterol daily, which has not been studied or approved for asthma and may increase cardiovascular adverse effects 1.

Appropriate Yellow Zone Management Strategy

Step Up the Corticosteroid Dose, Not the Frequency

• If inadequate control occurs on Breo 100/25 mcg once daily, switch to Breo 200/25 mcg once daily – the FDA label specifically states that "for patients who do not respond adequately to BREO ELLIPTA 100/25 mcg once daily, increasing the dose to BREO ELLIPTA 200/25 mcg once daily may provide additional improvement in asthma control" 1.
• This approach doubles the inhaled corticosteroid (fluticasone furoate from 100 to 200 mcg) while maintaining the same once-daily vilanterol dose of 25 mcg 1.

Use Rescue Medication for Acute Symptoms

• Albuterol (short-acting beta-agonist) should be used for immediate relief when asthma symptoms arise between Breo doses 1.
• Written asthma action plans that include specific instructions for rescue medication use reduce emergency department visits and hospitalizations 2.

Clinical Trial Evidence Supports Once-Daily Dosing Only

• All phase III trials evaluated Breo at one inhalation once daily – no studies have examined twice-daily dosing or doubling the number of inhalations 3, 4, 5.
• Efficacy was demonstrated with once-daily administration – FF/VI 100/25 mcg once daily significantly improved lung function, reduced rescue medication use, and increased symptom-free periods compared to fluticasone alone 4, 5.
• Safety data are limited to once-daily dosing – the 52-week safety trial evaluated only one inhalation daily, and adverse events were similar to comparators at this frequency 3.

Common Pitfall: Confusing Breo with Older ICS/LABA Products

• Breo is not like twice-daily combination inhalers – unlike fluticasone propionate/salmeterol (Advair), which is dosed twice daily, Breo contains a 24-hour long-acting beta-agonist (vilanterol) designed for once-daily use 1.
• The pharmacokinetics of vilanterol do not support twice-daily dosing – vilanterol provides sustained bronchodilation over 24 hours, and administering it twice daily would result in drug accumulation and increased risk of tachycardia, tremor, and other beta-agonist side effects 3.

Practical Yellow Zone Algorithm

1. Confirm the patient is using Breo correctly – once daily at the same time, with mouth rinsing after inhalation 1.
2. Increase rescue albuterol use as needed for acute symptoms (this is the appropriate yellow zone intervention for immediate symptom relief) 1.
3. If yellow zone symptoms persist or recur frequently (e.g., SABA use >2 days/week), contact the provider to switch from Breo 100/25 mcg to Breo 200/25 mcg once daily 6, 1.
4. Do not instruct the patient to take 2 puffs of Breo 100/25 mcg – this violates FDA labeling and exposes the patient to unapproved vilanterol doses 1.

Caveat: Asthma Action Plans Should Specify Controller Adjustments

• Traditional yellow zone plans often recommend doubling inhaled corticosteroids – this strategy was developed for twice-daily ICS or ICS/LABA products and does not translate to once-daily Breo 2.
• Asthma action plans for patients on Breo should specify switching to the higher-strength product (200/25 mcg) rather than increasing the number of inhalations 2, 1.